GSK Expects FY23 Turnover To Increase 12-13% Y/Y Versus Prior Range Of 8-10%; Adjusted EPS Growth Expected To Be 17-20% Compared To Prior Guidance Of 14%-17%
Portfolio Pulse from Benzinga Newsdesk
GlaxoSmithKline (GSK) has updated its FY23 turnover forecast, now expecting an increase of 12-13% Y/Y, up from the previous range of 8-10%. The company also anticipates adjusted EPS growth to be 17-20%, compared to the prior guidance of 14%-17%.

November 01, 2023 | 8:02 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
GSK has raised its FY23 turnover and adjusted EPS growth forecasts. This indicates a positive outlook for the company's future performance, which could potentially lead to a short-term increase in its stock price.
GSK's raised forecasts for FY23 turnover and adjusted EPS growth suggest that the company is expecting stronger financial performance than previously anticipated. This positive outlook could make the company's stock more attractive to investors, potentially leading to a short-term increase in its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100